Clinical Trial Update: Rotating Pazopanib and Everolimus to Avoid Resistance [Phase 2]

View source ↗

Summary

A Phase 2 study examining rotating pazopanib and everolimus to prevent therapy resistance in clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Netherlands Working Group on Immunotherapy of Oncology | Conditions: Clear Cell Renal Carcinoma | Phase 2 | Status: COMPLETED